The DOI matches its Crossref record; 62 of the 64 references it cites were found in a registry or an index.
Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain
Open accessPublished version of a preprint
Abstract
A population of more than six million people worldwide at high risk of Alzheimer’s disease (AD) are those with Down Syndrome (DS, caused by trisomy 21 (T21)), 70% of whom develop dementia during lifetime, caused by an extra copy of β-amyloid-(Aβ)-precursor-protein gene. We report AD-like pathology in cerebral organoids grown in vitro from non-invasively sampled strands of hair from 71% of DS donors. The pathology consisted of extracellular diffuse and fibrillar Aβ deposits, hyperphosphorylated/pathologically conformed Tau, and premature neuronal loss. Presence/absence of AD-like pathology was donor-specific (reproducible between individual organoids/iPSC lines/experiments). Pathology could be triggered in pathology-negative T21 organoids by CRISPR/Cas9-mediated elimination of the third copy of chromosome 21 gene BACE2 , but prevented by combined chemical β and γ-secretase inhibition. We found that T21 organoids secrete increased proportions of Aβ-preventing (Aβ1–19) and Aβ-degradation products (Aβ1–20 and Aβ1–34). We show these profiles mirror in cerebrospinal fluid of people with DS. We demonstrate that this protective mechanism is mediated by BACE2 -trisomy and cross-inhibited by clinically trialled BACE1 inhibitors. Combined, our data prove the physiological role of BACE2 as a dose-sensitive AD-suppressor gene, potentially explaining the dementia delay in ~30% of people with DS. We also show that DS cerebral organoids could be explored as pre-morbid AD-risk population detector and a system for hypothesis-free drug screens as well as identification of natural suppressor genes for neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence in preclinical models demonstrates that genes other than APP being in three copies modify aspects of DSAD, such as cognition and amyloid-β load [1, 50, 70]”
From Apolipoprotein E abundance is elevated in the brains of individuals with Down syndrome–Alzheimer’s disease (2025) · cites this paper as [1]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Self-citationAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876 · cited 1×
“BACE1 is the main β -secretase in the brain [9], whereas the expression and function of its homologue BACE2 (encoded by a chromosome 21 gene) remain less clear [10, 11].”
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Self-citationHigh-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects
Kleinstiver, B. P., Pattanayak, V., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Zheng, Z., & Joung, J. K. (2016) · Nature · doi:10.1038/nature16526 · Cited by 2,673
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
Generation of cerebral organoids from human pluripotent stem cells
Lancaster, M. A., & Knoblich, J. A. (2014) · Nature Protocols · doi:10.1038/nprot.2014.158 · Cited by 1,823
The coming of age of chaperone-mediated autophagy
Kaushik, S., & Cuervo, A. M. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0001-6 · Cited by 1,407
Rovelet‐Lecrux, A., Hannequin, D., Raux, G., Meur, N. L., Laquerrière, A., Vital, A., Dumanchin‐Njock, C., Feuillette, S., Brice, A., Vercelletto, M., et al. (2005) · Nature Genetics · doi:10.1038/ng1718 · Cited by 1,284
Self-citation
Flagged first, then by citations
2 of the 64 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–127 of 127
Promising Prospects for Human Cerebral Organoids to Advance Alzheimer's Disease Research
López, V., Rosca, A., Liste, I., Mateos-Martínez, P., Coronel, R., González-Sastre, R., Martín-Benito, S., & López, V. (2023) · Progress in Neurobiology · doi:10.60124/j.pneuro.2023.20.05 · Cited by 1
Morphogenetic Designs, and Disease Models in Central Nervous System Organoids
Bock, M., Hong, S. J., Zhang, S., Yu, Y., Lee, S., Shin, H.-E., Choi, B. H., & Han, I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147750 · Cited by 3
Wu, Y., Cleverley, K., & Wiseman, F. K. (2025) · PLoS ONE · doi:10.1371/journal.pone.0316822 · Cited by 1
Self-citationInterplay between DYRK1A dosage and aneuploidy-induced neuropathology in Down syndrome
Nambara, T., Lee, J. Y., Minami, M., Okamoto, S., Kawatani, K., Kusakabe, H., Yoshimatsu, H., Hirata, K., Yoshimi, K., Mashimo, T., et al. (2026) · Communications Biology · doi:10.1038/s42003-026-09902-6 · Cited by 1
Plećaš, A., Gough, G., Grčević, D., Jackowiak, H., Skieresz‐Szewczyk, K., Horaček, M., Šimunić, I., Krsnik, Ž., Mitrečić, D., Murray, A., et al. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08956-y · Cited by 1
Self-citationTschirner, S. K., Zuchero, Y. J. Y., Getz, J. A., Müller, S. A., Nalbach, K., Kennedy, M. E., Lewcock, J. W., & Lichtenthaler, S. F. (2025) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2025.101012 · Cited by 1
Endosomal structure and APP biology are not altered in preclinical cellular models of Down syndromePreprint
Cannavo, C., Cleverley, K., Maduro, C., Mumford, P., MOULDING, D. A., Fisher, E., & Wiseman, F. K. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.30.474570
Self-citationCannavo, C., Cleverley, K., Maduro, C., Mumford, P., MOULDING, D. A., Fisher, E., & Wiseman, F. K. (2022) · PLoS ONE · doi:10.1371/journal.pone.0262558
Self-citationIn vivo and in vitro models for research on Down syndrome
Ganguly, B. B. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90456-8.00013-2 · Cited by 1
Biomarcadores amiloidogênicos na síndrome de Down
Bram, J. M. D. F. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2023.tde-20092023-163847
Jandy, M., Hu, H., Liu, Y., & Bhattacharyya, A. (2025) · Springer eBooks · doi:10.1007/978-3-031-78611-2_7
The potential of brain organoids in addressing the heterogeneity of synucleinopathies
Diao, X.-J., Soto, C. A., Wang, F., Wang, Y., Wu, Y., & Mukherjee, A. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-05686-w
Bartesaghi, R., Chen, X., Johnstone, A. D., Das, U., & Mobley, W. C. (2025) · Springer eBooks · doi:10.1007/978-3-031-89307-0_19
He, T., & Katušić, Z. S. (2025) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823251371040
Use of brain organoids for Parkinson's disease and Alzheimer's diseases
Kumari, S., Sharma, P., Dhapola, R., Ashvin, Chaudhary, B. N., Vellingiri, B., & HariKrishnaReddy, D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29898-1.00015-0
Tschirner, S. K., Schmidt, A., Ito, M., Hyakkoku, K., Yoshimura, A., Müller, S. A., Horiguchi, N., & Lichtenthaler, S. F. (2025) · PROTEOMICS · doi:10.1002/pmic.70082
Wu, Y., Mumford, P., Noy, S., Cleverley, K., Mrzyglod, A., Luo, D., van Dalen, F., Verdoes, M., Fisher, E., & Wiseman, F. K. (2023) · Figshare · doi:10.6084/m9.figshare.23949660
Self-citationLattke, M., Tan, W. L., Sukumaran, S. K., Utami, K. H., Sintes, M., Sakthivel, S., Tan, J., Lim, A. T. J., Bansal, V. A., Rekopoulou, K., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.29.696602
Self-citationLarsen, E. C., Moon, J. E., King, O. D., & Lawrence, J. B. (2026) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2026.02.014
Béguin, A. (2024) · theses.fr (ABES) · doi:10.70675/91026eb5zf996z44a3zad54z8065cd33958b
Zakaria, J. A. D., & Vassar, R. J. (2026) · Topics in medicinal chemistry · doi:10.1007/7355_2026_188
Balaji, P., & Jayaprakash, N. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02572-9
New mouse models for Down syndrome Alzheimer's disease
Wiseman, F. K. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261488873
Self-citation
Metadata
- Authors
- Alić, I., Goh, P. A., Murray, A., Portelius, E., Gkanatsiou, E., Gough, G., Mok, K. Y., Koschut, D., Brunmeir, R., Yeap, Y. J., O’Brien, N. L., Groet, J., Shao, X., Havlicek, S., Dunn, N. R., Kvartsberg, H., Brinkmalm, G., Hithersay, R., Startin, C., Hamburg, S., Phillips, M., Pervushin, K., Turmaine, M., Wallon, D., Rovelet-Lecrux, A., Soininen, H., Volpi, E., Martin, J. E., Foo, J. N., Becker, D. L., Rostagno, A., Ghiso, J., Krsnik, Ž., Šimić, G., Kostović, I., Mitrečić, D., LonDownS Consortium, Strydom, A., Fisher, E., Wiseman, F., Nizetic, D., Hardy, J., Tybulewicz, V., Karmiloff-Smith, A., Francis, P. T., Blennow, K., Strydom, A., Hardy, J., Zetterberg, H., & Nižetić, D.
- Affiliations
- Queen Mary University of London (GB)
- Nanyang Technological University (SG)
- University of Gothenburg (SE)
- UCL Queen Square Institute of Neurology (GB)
- Agency for Science, Technology and Research (SG)
- King's College London (GB)
- University College London (GB)
- Inserm (FR)
- University of Eastern Finland (FI)
- University of Westminster (GB)
- New York University (US)
- University of Zagreb (HR)
- The Francis Crick Institute (GB)
- ORCID
- Alić, Ivan
- Goh, Pollyanna A.
- Murray, Aoife
- Portelius, Erik
- Gkanatsiou, Eleni
- Gough, Gillian
- Mok, Kin Y.
- Koschut, David
- Brunmeir, Reinhard
- Yeap, Yee Jie
- O’Brien, Niamh L.
- Shao, Xiaowei
- Dunn, N. Ray
- Kvartsberg, Hlin
- Brinkmalm, Gunnar
- Hithersay, Rosalyn
- Startin, Carla
- Hamburg, Sarah
- Pervushin, Konstantin
- Wallon, David
- Soininen, Hilkka
- Volpi, Emanuela
- Martin, Joanne E.
- Foo, Jia Nee
- Becker, David L.
- Rostagno, Agueda
- Ghiso, Jorge
- Krsnik, Željka
- Šimić, Goran
- Kostović, Ivica
- Mitrečić, Dinko
- Fisher, Elizabeth
- Wiseman, Frances
- Tybulewicz, Victor
- Francis, Paul T.
- Blennow, Kaj
- Zetterberg, Henrik
- Nižetić, Dean
- Venue
- Molecular Psychiatry
- Published
- 2020-07-10
- Volume
- 26
- Issue
- 10
- Pages
- 5766-5788
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- PMC
- PMC8190957
- OpenAlex
- W3041871366
- Cited by
- 123
- References
- 64
- Citations by year
- 2026: 9 · 2025: 22 · 2024: 16 · 2023: 21 · 2022: 20 · 2021: 24 · 2020: 9
- FWCI
- 11.73
- Type
- journal article
- Language
- en
- Update notices
- correction (2021-07-16)
- Open access
- hybrid
- doi.org
- Locations
- Molecular Psychiatry (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DR-NTU (Nanyang Technological University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Research Portal (King's College London) (submittedVersion, cc-by)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion, cc-by)
- WestminsterResearch (University of Westminster) (submittedVersion, cc-by)
- The Francis Crick Institute (cc-by)
- Funders
- BrightFocus Foundation (A2015275S)
- Wellcome Trust (FP7/2007–2013, 098330, 608765, 098330/Z/12/Z, 217199, 217199/Z/19/Z, 098327/Z/12/Z)
- Francis Crick Institute (10194)
- EU Joint Programme – Neurodegenerative Disease Research
- Alzheimer's Society
- Zaklade Adris
- Parkinson's UK (G-0907)
- European Commission (608765, GA KK 01 1 1 01 0007, 2007–2013, FP7 2007-2013, FP7/2007, IP-2019-04-3584)
- Rosetrees Trust
- National Research Foundation (NRF-NRFF2016-03)
- National Research Foundation Singapore (NRFF2016, NRF-NRFF2016-03)
- Agence Nationale de la Recherche (ANR-17-JPCD-0003)
- Royal Swedish Academy of Sciences (2017-00915)
- Fondation pour la Recherche Médicale
- Hjärnfonden (FO2017‑0243, FO2017, ALFGBG-715986)
- Vetenskapsrådet (FP7/2007-2013, 2017-00915, (#ALFGBG-715986, ALFGBG-720931, FO2017-0243)
- Hrvatska Zaklada za Znanost (IP-2019-04, IP-2016-06-9451, PZS-2019-02-4277, IP-2019-04-3584, GA KK01.1.1.01.0007, KK01.1.1.01.0007, 2019‐04‐3584)
- UK Dementia Research Institute (#2017-00915, ALFGBG-715986, FO2017-0243, -0243, -715986)
- National Institutes of Health (IP-2019-04-3584, FP7/2007-2013, 1rf1ag059695-01a1, KK.01.1.1.01.0007, GA KK01.1.1.01.0007)
- Medical Research Council (FP7/20072013, MR/L501542/1, MR/S011277/1, MR/R024901/1, MR/N026004/1, 608765, MR/T002581/1)
- National Medical Research Council (NMRC/CIRG/1438/ 2015)
- European Regional Development Fund (GA KK01.1.1.01.0007, FP7/2007‐2013, 2007 – 2013, KK.01.1.1.01.0007, IP-2019-04-3584)
- National Institute on Aging (RF1 AG059695)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Down syndrome and intellectual disability research
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Down syndrome, Alzheimer's disease, BACE2, brain organoids, amyloid-beta, tau hyperphosphorylation, BACE1 inhibitors, gene dosage, beta-secretase inhibition, gamma-secretase inhibition, cerebrospinal fluid biomarkers, neurodegeneration, drug screening
- MeSH terms
- Alzheimer Disease, Brain, Down Syndrome, Humans, Organoids, Trisomy, Genes, Suppressor, Amyloid beta-Peptides, Aspartic Acid Endopeptidases, Amyloid Precursor Protein Secretases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
